Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights a concentrated trend of domestic innovative drug collaborations and transactions as the year ends, with expectations for value recovery in 2026 [1][4] - The overall market performance shows a decline, with the Hang Seng Index down 0.8% and the Hang Seng Healthcare Index down 4.3% during the week [4][7] - The report emphasizes the importance of stock selection logic returning to fundamentals and valuations, focusing on stocks that are currently undervalued with expected fundamental improvements [4] Valuation Summary - The report provides a detailed valuation overview of various companies, indicating target prices and earnings per share estimates for FY25E and FY26E, along with their respective price-to-earnings ratios [3] - Notable companies with "Buy" ratings include AstraZeneca, BeiGene, and Hansoh Pharmaceutical, with target prices significantly above current trading prices [3] Market Trends - The report notes a slight decrease in domestic institutional holdings through the Hong Kong Stock Connect, while foreign holdings remain stable [33] - The report identifies a trend of increasing positions in leading innovative pharmaceutical companies by domestic investors, particularly in companies like Heng Rui Medicine and Rongchang Bio [36] Investment Insights - The report mentions several significant business development (BD) transactions exceeding $1 billion, indicating a robust pipeline for innovative drugs [4][5] - It recommends focusing on specific segments such as innovative drugs and CXO companies that are expected to benefit from downstream recovery and high market demand [4]

Core Viewpoint - The Hong Kong stock market has seen a surge in refinancing activities this year, with placements becoming the preferred method for companies due to their efficiency, flexibility, and cost advantages [1][3]. Group 1: Market Activity - Hong Kong listed companies have raised nearly 350 billion HKD through placements, rights issues, and consideration issues this year, with placements accounting for almost 90% of the total [1][3]. - The total amount raised through placements alone reached approximately 312.4 billion HKD, representing 89.61% of the total refinancing [3][7]. Group 2: Industry Insights - Key industries leading the placements include hardware equipment, automotive and parts, biomedicine, and software services, with hardware equipment raising 600.07 billion HKD [4][5]. - Notable contributions from specific companies include Xiaomi Group raising 426 billion HKD in the hardware sector and BYD raising 435.09 billion HKD in the automotive sector [4][7]. Group 3: Fund Utilization - The funds raised through placements are primarily allocated for research and development, business expansion, international market development, and optimizing capital structure [9]. - Companies like SenseTime and BYD have specified that their raised funds will support core business development, AI infrastructure, and overseas market expansion [9]. Group 4: Market Conditions - The active refinancing in the Hong Kong market is attributed to increased market activity, rising trading volumes, and valuation recovery, providing an excellent window for companies to refinance [10]. - Analysts predict that the liquidity in the Hong Kong market will continue to improve, driven by the "wealth effect" and increasing participation from mainland investors [10].

Group 1 - The Hong Kong stock market has seen active refinancing this year, with placements becoming a key method due to their efficiency, flexibility, and cost advantages [1][2] - As of this year, Hong Kong listed companies have raised nearly 350 billion HKD through placements, rights issues, and consideration issues, with placements accounting for nearly 90% of the total [1][2] - Discounted placements have become the mainstream method, with most companies adopting this strategy to attract investors [1][2] Group 2 - The technology and biopharmaceutical sectors dominate the placement market, with hardware, automotive, and software services also being significant contributors [3] - Notable placements include Xiaomi Group raising 426 billion HKD in the hardware sector and BYD raising 435 billion HKD in the automotive sector [3] - Approximately 40% of the total refinancing this year has come from technology companies, reflecting strong investor confidence in the tech sector [3] Group 3 - The funds raised through placements are primarily allocated for research and development, business expansion, international market development, and operational capital [4][5] - Companies like SenseTime plan to use 30% of their placement proceeds for core business development and AI infrastructure, while BYD aims to enhance its technological capabilities and expand overseas [4][5] - The active refinancing environment is supported by increased market activity, rising transaction volumes, and valuation recovery, providing an excellent window for listed companies [5]

银行股延续弱势，低开低走后全天回撤，截至收盘下跌1.18%。其中农业银行大跌2.74%，大新银行下 跌2.48%，邮储银行下跌2.29%，大新金融、中信银行、建设银行等股跌幅均在2%上方。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生科技低开低走大跳水，截至收盘下跌2.3%。其中阿里巴巴大跌2.96%，网易下跌2.59%，京东集 团、小米集团、中芯国际等股跌幅均在2%上方。 恒生医疗低开低走后探底回升，但力度有限，截至收盘下跌1.88%。其中三生制药下跌2.21%，石药集 团下跌2%，京东健康、翰森制药、药明生物等股跌幅均在1%上方。 同步内地市场，今天港股低开低走后全天弱势，截至收盘下跌1.54%。恒生科技跌幅居前，互联网、医 疗、大消费。银行等紧随其后。 ...

Group 1 - The Hong Kong stock market has stabilized, maintaining a narrow range around the mid-axis during the morning session, with slight gains in consumer and technology sectors, while the internet and healthcare sectors experienced a downturn [1] - The consumer sector showed signs of recovery, with a slight increase of 0.32% by midday, driven by stocks such as Li Ning up 4.37%, Shenzhou International up 2.26%, and several others like Stone Pharmaceutical, Lao Pu Gold, WuXi Biologics, and Pop Mart all rising over 1% [3] - The technology sector also saw a minor increase of 0.14% by midday, with Meituan up 1.21%, while major players like JD Group, Alibaba, Tencent Holdings, and SMIC posted slight gains; however, BYD and NetEase faced minor declines [3] Group 2 - The healthcare sector had a lackluster performance, with Stone Pharmaceutical up 1.9% and WuXi Biologics up 1.68%, while other stocks like BeiGene, Innovent Biologics, and 3SBio saw slight increases; in contrast, companies like CanSino Biologics, China Biologic Products, JD Health, and Hansoh Pharmaceutical experienced minor declines [3]

作为医疗类主题的权益基金，泰康医疗健康股票自然重仓医药股，从今年三季报中的前十大重仓股 看，该基金持有晶泰控股、康龙化成、方舟健客、三生制药、昭衍新药、九安医疗、奕瑞科技、羚锐制 药、百普赛斯、毕得医药。但从走势上看，尽管多数个股在三季度都随市场整体上涨而大涨，然而其 A/C份额在三季度里却仅上涨了5.43%和5.30%，不知道是不是多数重仓股已经被更换的原因。 如果仅以三季度的重仓股看，进入到四季度，这些个股大都出现回调，比如第一大重仓股晶泰控股 就在四季度以来下跌了近35%，方舟健客更是在10月份后大跌38%，还有多只个股跌幅都超过10%。而 唯一一只今年前三个季度始终出现在前十大重仓股中的羚锐制药，股价在2025年度内还处于小幅下跌状 态。 (责任编辑：康博) 来源：天天基金网 中国经济网北京12月17日讯 今日，新浪发布《牛市亏损！泰康基金："医疗健康A"年内净值下跌 12.54%，成立以来仍处于浮亏》一文。文中称，截至2025年12月15日，泰康医疗健康A年内净值下跌 12.54%，成立3年多该基金净值累计跌超8%。该基金部分三季度末重仓股自四季度以来股价下跌超过 30%，包括晶泰控股、方舟健客等。 ...

Core Viewpoint - The Hong Kong innovation drug sector is experiencing a correction, leading to increased capital inflow into core assets, particularly the Hong Kong Stock Connect Innovation Drug ETF (520880), which has seen a significant increase in fund subscriptions despite a market downturn [1][6]. Group 1: Market Performance - The Hong Kong Stock Connect Innovation Drug ETF (520880) has experienced a decline of over 22% since early September, reaching a five-month low as of December 16 [1][6]. - Despite the price drop, the ETF has seen a net subscription for seven consecutive days, with the total fund shares rising to 4.172 billion, marking a new high since its inception [1][6]. Group 2: Market Analysis - The overall pressure on the Hong Kong market in December has made high-growth sectors like innovation drugs more susceptible to capital outflows [3][8]. - Expectations of a potential interest rate hike by the Bank of Japan and a tightening of external liquidity are contributing to increased volatility in the sector [3][8]. - Year-end risk aversion and profit-taking by institutional investors are also influencing market dynamics [3][8]. Group 3: Investment Logic - The underlying drivers for the growth of China's innovation drug sector, including accelerated international expansion, technological upgrades, and commercialization, remain intact [3][8]. - Upcoming industry events, such as clinical data progress and significant business development transactions, are expected to provide positive catalysts for the sector, with a focus on the first quarter of 2026 [3][8]. Group 4: ETF Characteristics - The Hong Kong Stock Connect Innovation Drug ETF (520880) is characterized by three unique advantages: it exclusively covers innovation drug companies, has a high concentration of leading firms with over 72% weight in the top ten stocks, and employs measures to control risks associated with less liquid components [3][9]. - As of November 30, the ETF's scale was 2.142 billion, with an average daily trading volume of 458 million, making it the largest and most liquid ETF tracking the same index [4][11].

来源：新浪基金 今日（12月16日）A股三大指数集体回调，沪指跌逾1%，创业板指跌超2%，全市场超4300只个股下 跌，仅千余只个股收涨，沪深两市成交额1.72万亿元，较昨日小幅缩量。 为何市场深度回调？发生了什么？从全球的角度来看，最大的变数可能是日本央行加息箭在弦上，利率 料升至30年新高！日本央行12月18日-19日将召开金融政策决定会议，最可能的方案是加息0.25%至 0.75%，达到1995年以后30年来的最高利率水平。 ①重仓互联网龙头的——港股互联网ETF（513770）近8日狂揽8.26亿元； ②100%创新药研发标的——港股通创新药ETF（520880）近6日连续吸金超2亿元； ③自带"科技+红利"哑铃策略的——香港大盘30ETF（520560）近9日连续获资金净流入，合计金额7089 万元； ④全市场首只聚焦"港股芯片"产业链的——港股信息技术ETF（159131）继昨日资金净流入639万元， 今日盘中再获实时净申购500万份。 盘面上港股市场持续走弱的表现，可能与日元套息交易走弱存在一定关系。多数人士认为，日本央行加 息不会对当下的市场造成太大的冲击。虽然日本央行可能出售 ETF，但套息 ...

Market Overview - The A-share market experienced a collective pullback, with the Shanghai Composite Index dropping over 1% and the ChiNext Index falling more than 2%, as over 4,300 stocks declined while only about 1,000 stocks rose [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.72 trillion yuan, slightly lower than the previous day [1] Global Influences - The potential interest rate hike by the Bank of Japan is a significant factor, with expectations of an increase of 0.25% to 0.75%, reaching the highest level in 30 years [1] - The weakening of the Hong Kong stock market may be related to the decline in yen carry trades, although many believe the impact of the Bank of Japan's rate hike will be limited [1] Fund Flows - There is a notable inflow of capital into quality Hong Kong stocks, with several ETFs attracting significant investments: - The Hong Kong Internet ETF (513770) has seen inflows of 826 million yuan over the past eight days [1] - The Hong Kong Innovation Drug ETF (520880) has attracted over 200 million yuan in six days [1] - The Hong Kong Large Cap 30 ETF (520560) has received a total of 70.89 million yuan in net inflows over nine days [1] - The Hong Kong Information Technology ETF (159131) has also seen net inflows [1] Sector Focus - The Hong Kong Medical ETF (159137) is currently being launched, focusing on 48 leading companies in the medical sector, with 39 being exclusive to the Hong Kong market [3] - The market is viewed as being at a strategic opportunity point, with valuations at a global low and strong capital inflows, suggesting limited downside and significant upside potential for long-term investors [3] Digital Currency and Financial Technology - The promotion of digital RMB smart contracts is enhancing consumption policies, with the largest financial technology ETF (159851) rising against the market trend, gaining 0.75% [5][6] - The financial technology sector is expected to see increased activity due to regulatory changes that encourage insurance companies to invest more in A-shares [8] Innovation Drug Sector - The Hong Kong Innovation Drug ETF (520880) has been under pressure, reaching a new low, with 29 out of 37 covered companies declining [10] - Despite the downturn, there is a significant net inflow into the ETF, indicating a potential buying opportunity as the sector adjusts [11][13] AI and Internet Sector - The Hong Kong Internet ETF (513770) has experienced a decline of 21% from its yearly high, but remains attractive for long-term investment due to its relatively low valuation compared to other indices [21] - The ETF has seen continuous inflows, indicating strong buying interest despite recent market volatility [18][23]

Core Viewpoint - The Hong Kong Stock Connect innovative drug ETF (520880) is experiencing a significant decline, reaching a new low in nearly five months, with a drop of 1.91% and nearing its initial listing price level. The underlying 37 innovative drug companies saw 29 decline and 8 rise, indicating a challenging market environment for the sector [1][9]. Market Performance - In December, the Hong Kong Stock Connect innovative drug ETF (520880) has only recorded two days of gains over 12 trading days, reflecting a broader market pressure. The innovative drug sector, characterized by high valuation elasticity, is particularly vulnerable to capital outflows [10]. - The ETF has seen a significant adjustment, with a drop of over 22% since early September, indicating a substantial correction that may have released some elastic space for future recovery [4][12]. Fund Flows - Recent market adjustments have prompted noticeable buying activity, with over 75 million yuan net subscriptions in a single day, leading to a total of over 200 million yuan in net inflows over six consecutive days. The ETF's share has risen to a new high of 4.148 billion shares [2][12]. Technical Analysis - The technical indicators for the Hong Kong Stock Connect innovative drug ETF (520880) suggest a bearish trend, with the MACD showing a clear downtrend. The DIF is below the DEA, indicating strong downward momentum in the short term [5][12]. Long-term Outlook - The fundamental drivers for the development of China's innovative drug sector, including accelerated international expansion, technological upgrades, and commercialization, remain unchanged. Upcoming industry events and breakthroughs are expected to provide positive catalysts, with a focus on the first quarter of 2026 [14]. ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) is noted for its unique advantages, including a pure focus on innovative drugs without CXO companies, a significant concentration of leading firms with over 72% weight in the top ten holdings, and controlled risks through forced de-weighting of less liquid stocks [15][16][17].